OncoTelic Overview

  • Year Founded
  • 1988

Year Founded

  • Status
  • Public

  • Employees
  • 13

Employees

  • Stock Symbol
  • OTLC

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.01
  • (As of Friday Closing)

OncoTelic General Information

Description

Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. OT-101 is its flagship immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, AL-101, and Oxi4503.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 29397 Agoura Road
  • Suite 107
  • Agoura Hills, CA 91301
  • United States
+1 (650)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 29397 Agoura Road
  • Suite 107
  • Agoura Hills, CA 91301
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoTelic Stock Performance

As of 20-Nov-2026, OncoTelic’s stock price is $0.01. Its current market cap is $5.9M with 458M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.01 $0.01 $0.01 - $0.10 $5.9M 458M 389K $0.58

OncoTelic Financials Summary

As of 30-Sep-2026, OncoTelic has a trailing 12-month revenue of $250K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 22,653 47,187 26,321 26,920
Revenue 250 0 0 70
EBITDA 359,928 361,460 (3,922) (7,161)
Net Income 247,432 249,280 (4,524) (7,903)
Total Assets 393,813 393,088 26,677 30,015
Total Debt 14,325 13,912 13,088 12,574
Public Fundamental Data provided by Morningstar, Inc. disclaimer

OncoTelic Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore OncoTelic‘s full profile, request access.

Request a free trial

OncoTelic Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatme
Biotechnology
Agoura Hills, CA
13 As of 2025

Palo Alto, CA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoTelic Competitors (4)

One of OncoTelic’s 4 competitors is Immune-Onc Therapeutics, a Venture Capital-Backed company based in Palo Alto, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immune-Onc Therapeutics Venture Capital-Backed Palo Alto, CA
Lyell Immunopharma Formerly VC-backed South San Francisco, CA
Nkarta Therapeutics Formerly VC-backed South San Francisco, CA
Pyxis Oncology Formerly VC-backed Boston, MA
To view OncoTelic’s complete competitors history, request access »

OncoTelic Patents

OncoTelic Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026207089-A1 Methods and compositions for antisense cancer therapeutics Pending 26-Mar-2025
WO-2025250885-A1 In situ tumor-infiltrating lymphocyte therapeutics for cancer Pending 31-May-2024
AU-2024388416-A1 Structures and methods for autonomous agents Pending 29-Nov-2023
EP-4816939-A1 Structures and methods for autonomous agents Pending 29-Nov-2023
US-20260329914-A1 Structures and methods for autonomous agents Pending 29-Nov-2023 G06F16/3347
To view OncoTelic’s complete patent history, request access »

OncoTelic Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoTelic Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore OncoTelic‘s full profile, request access.

Request a free trial

OncoTelic Investments & Acquisitions (2)

OncoTelic’s most recent deal was a Joint Venture with GMP Biotechnology. The deal was made on 31-Mar-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
GMP Biotechnology 31-Mar-2022 Joint Venture Drug Discovery
Mateon Therapeutics 25-Apr-2019 Merger/Acquisition Drug Discovery
To view OncoTelic’s complete investments and acquisitions history, request access »

OncoTelic ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view OncoTelic’s complete esg history, request access »

OncoTelic Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
OncoTelic (Necroptosis Cancer Therapy Assets) Agoura Hills, CA

OncoTelic FAQs

  • When was OncoTelic founded?

    OncoTelic was founded in 1988.

  • Where is OncoTelic headquartered?

    OncoTelic is headquartered in Agoura Hills, CA.

  • What is the size of OncoTelic?

    OncoTelic has 13 total employees.

  • What industry is OncoTelic in?

    OncoTelic’s primary industry is Biotechnology.

  • Is OncoTelic a private or public company?

    OncoTelic is a Public company.

  • What is OncoTelic’s stock symbol?

    The ticker symbol for OncoTelic is OTLC.

  • What is the current stock price of OncoTelic?

    As of 20-Nov-2026 the stock price of OncoTelic is $0.01.

  • What is the current market cap of OncoTelic?

    The current market capitalization of OncoTelic is $5.9M.

  • What is OncoTelic’s current revenue?

    The trailing twelve month revenue for OncoTelic is $250K.

  • Who are OncoTelic’s competitors?

    Immune-Onc Therapeutics, Lyell Immunopharma, Nkarta Therapeutics, and Pyxis Oncology are competitors of OncoTelic.

  • What is OncoTelic’s annual earnings per share (EPS)?

    OncoTelic’s EPS for 12 months was $0.58.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process